Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Imalumab |
Synonyms | |
Therapy Description |
Imalumab (BAX069) is a monoclonal antibody that binds to macrophage migration inhibitory factor (MIF), which may lead to inhibition of the MAPK and PI3K/mTOR/Akt pathways, and subsequent tumor cell proliferation (PMID: 32207164). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Imalumab | BAX-69|BAX069|BAX69 | Imalumab (BAX069) is a monoclonal antibody that binds to macrophage migration inhibitory factor (MIF), which may lead to inhibition of the MAPK and PI3K/mTOR/Akt pathways, and subsequent tumor cell proliferation (PMID: 32207164). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02540356 | Phase Ib/II | Imalumab | Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer | Terminated | USA | 0 |
NCT02448810 | Phase II | Fluorouracil + Leucovorin Imalumab Panitumumab | Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer | Terminated | USA | 0 |